Atopic dermatitis

Molecular mechanism, clinical aspects and new therapeutical approaches

E. Galli, R. Cicconi, P. Rossi, A. Casati, E. Brunetti, G. Mancino

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a genetically determinated, chronic inflammatory skin disorder associated with cutaneous erythema and severe pruritus, affecting 10-15% of children with increasing incidence and socio-economical relevance. Frequently, AD is associated with development of allergic rhinitis and/or asthma later in childhood. In most of patients AD is associated with a sensitization to food and/or environmental allergens and increased serum-IgE, while only a fewer percentage missed links to the classical atopic diathesis. Currently investigated pathogenetic aspects of AD include imbalanced Th1/Th2 responses, altered prostaglandin metabolism, intrinsic defects in the keratinocyte function, delayed eosinophil apoptosis, and IgE-mediated facilitated antigen presentation by epidermal dendritic cells. An inflammatory response of the two-phase-type and the effects of staphylococcal superantigens (SAgs) are also reported. At present a standardized cure of AD and a consensus on therapeutical approach of the severe form of the disease have not been established. Current management of AD is directed to the reduction of cutaneous inflammation and infection, mainly by S. aureus, and to the elimination of exacerbating factors (irritants, allergens, emotional stresses). Since patient with AD show abnormalities in immunoregulation, therapy directed to adjustment of their immune function could represent an alternative approach, particularly in the severe form of the disease. In this review, we analyse the clinical and genetic aspects of AD, the related molecular mechanisms, and the immunobiology of the disease, focusing our attention on current treatments and future perspectives on this topic.

Original languageEnglish
Pages (from-to)127-138
Number of pages12
JournalCurrent Molecular Medicine
Volume3
Issue number2
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Atopic Dermatitis
Allergens
Skin
Immunoglobulin E
Social Adjustment
Superantigens
Langerhans Cells
Irritants
Disease Susceptibility
Antigen Presentation
Erythema
Pruritus
Keratinocytes
Psychological Stress
Eosinophils
Metabolism
Prostaglandins
Consensus
Asthma
Apoptosis

Keywords

  • Atopic dermatitis
  • Clinical aspects
  • Molecular mechanisms
  • Therapeutical approach

ASJC Scopus subject areas

  • Biochemistry

Cite this

Atopic dermatitis : Molecular mechanism, clinical aspects and new therapeutical approaches. / Galli, E.; Cicconi, R.; Rossi, P.; Casati, A.; Brunetti, E.; Mancino, G.

In: Current Molecular Medicine, Vol. 3, No. 2, 03.2003, p. 127-138.

Research output: Contribution to journalArticle

Galli, E. ; Cicconi, R. ; Rossi, P. ; Casati, A. ; Brunetti, E. ; Mancino, G. / Atopic dermatitis : Molecular mechanism, clinical aspects and new therapeutical approaches. In: Current Molecular Medicine. 2003 ; Vol. 3, No. 2. pp. 127-138.
@article{639b0e2775cb4115b18af109ddff9f1f,
title = "Atopic dermatitis: Molecular mechanism, clinical aspects and new therapeutical approaches",
abstract = "Atopic dermatitis (AD) is a genetically determinated, chronic inflammatory skin disorder associated with cutaneous erythema and severe pruritus, affecting 10-15{\%} of children with increasing incidence and socio-economical relevance. Frequently, AD is associated with development of allergic rhinitis and/or asthma later in childhood. In most of patients AD is associated with a sensitization to food and/or environmental allergens and increased serum-IgE, while only a fewer percentage missed links to the classical atopic diathesis. Currently investigated pathogenetic aspects of AD include imbalanced Th1/Th2 responses, altered prostaglandin metabolism, intrinsic defects in the keratinocyte function, delayed eosinophil apoptosis, and IgE-mediated facilitated antigen presentation by epidermal dendritic cells. An inflammatory response of the two-phase-type and the effects of staphylococcal superantigens (SAgs) are also reported. At present a standardized cure of AD and a consensus on therapeutical approach of the severe form of the disease have not been established. Current management of AD is directed to the reduction of cutaneous inflammation and infection, mainly by S. aureus, and to the elimination of exacerbating factors (irritants, allergens, emotional stresses). Since patient with AD show abnormalities in immunoregulation, therapy directed to adjustment of their immune function could represent an alternative approach, particularly in the severe form of the disease. In this review, we analyse the clinical and genetic aspects of AD, the related molecular mechanisms, and the immunobiology of the disease, focusing our attention on current treatments and future perspectives on this topic.",
keywords = "Atopic dermatitis, Clinical aspects, Molecular mechanisms, Therapeutical approach",
author = "E. Galli and R. Cicconi and P. Rossi and A. Casati and E. Brunetti and G. Mancino",
year = "2003",
month = "3",
doi = "10.2174/1566524033361564",
language = "English",
volume = "3",
pages = "127--138",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Atopic dermatitis

T2 - Molecular mechanism, clinical aspects and new therapeutical approaches

AU - Galli, E.

AU - Cicconi, R.

AU - Rossi, P.

AU - Casati, A.

AU - Brunetti, E.

AU - Mancino, G.

PY - 2003/3

Y1 - 2003/3

N2 - Atopic dermatitis (AD) is a genetically determinated, chronic inflammatory skin disorder associated with cutaneous erythema and severe pruritus, affecting 10-15% of children with increasing incidence and socio-economical relevance. Frequently, AD is associated with development of allergic rhinitis and/or asthma later in childhood. In most of patients AD is associated with a sensitization to food and/or environmental allergens and increased serum-IgE, while only a fewer percentage missed links to the classical atopic diathesis. Currently investigated pathogenetic aspects of AD include imbalanced Th1/Th2 responses, altered prostaglandin metabolism, intrinsic defects in the keratinocyte function, delayed eosinophil apoptosis, and IgE-mediated facilitated antigen presentation by epidermal dendritic cells. An inflammatory response of the two-phase-type and the effects of staphylococcal superantigens (SAgs) are also reported. At present a standardized cure of AD and a consensus on therapeutical approach of the severe form of the disease have not been established. Current management of AD is directed to the reduction of cutaneous inflammation and infection, mainly by S. aureus, and to the elimination of exacerbating factors (irritants, allergens, emotional stresses). Since patient with AD show abnormalities in immunoregulation, therapy directed to adjustment of their immune function could represent an alternative approach, particularly in the severe form of the disease. In this review, we analyse the clinical and genetic aspects of AD, the related molecular mechanisms, and the immunobiology of the disease, focusing our attention on current treatments and future perspectives on this topic.

AB - Atopic dermatitis (AD) is a genetically determinated, chronic inflammatory skin disorder associated with cutaneous erythema and severe pruritus, affecting 10-15% of children with increasing incidence and socio-economical relevance. Frequently, AD is associated with development of allergic rhinitis and/or asthma later in childhood. In most of patients AD is associated with a sensitization to food and/or environmental allergens and increased serum-IgE, while only a fewer percentage missed links to the classical atopic diathesis. Currently investigated pathogenetic aspects of AD include imbalanced Th1/Th2 responses, altered prostaglandin metabolism, intrinsic defects in the keratinocyte function, delayed eosinophil apoptosis, and IgE-mediated facilitated antigen presentation by epidermal dendritic cells. An inflammatory response of the two-phase-type and the effects of staphylococcal superantigens (SAgs) are also reported. At present a standardized cure of AD and a consensus on therapeutical approach of the severe form of the disease have not been established. Current management of AD is directed to the reduction of cutaneous inflammation and infection, mainly by S. aureus, and to the elimination of exacerbating factors (irritants, allergens, emotional stresses). Since patient with AD show abnormalities in immunoregulation, therapy directed to adjustment of their immune function could represent an alternative approach, particularly in the severe form of the disease. In this review, we analyse the clinical and genetic aspects of AD, the related molecular mechanisms, and the immunobiology of the disease, focusing our attention on current treatments and future perspectives on this topic.

KW - Atopic dermatitis

KW - Clinical aspects

KW - Molecular mechanisms

KW - Therapeutical approach

UR - http://www.scopus.com/inward/record.url?scp=0037333866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037333866&partnerID=8YFLogxK

U2 - 10.2174/1566524033361564

DO - 10.2174/1566524033361564

M3 - Article

VL - 3

SP - 127

EP - 138

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 2

ER -